< Return to Bears page

Life after Lipitor?

Looking at Pfizer in its current position, the picture isn't that pretty. Of the company's 2006 revenues of $48 billion, its blockbuster cholesterol drug Lipitor was responsible for $12.9 billion. That's all well and good, but Lipitor isn't going to be around forever. Pfizer’s key drug, cholesterol drug Lipitor, which accounted for about a quarter of Pfizer’s sales over the last 4 quarters and 65% of its cash flow according to Credit Suisse Pharmaceuticals analyst Catherine Arnold, goes off patent protection in 2010. That’s a huge worry.

With a patent expiration coming as soon as 2010, Lipitor (and it's 26% contribution to Pfizer's revenue) are going to be opened up to a wide range of new competitors, many of whom will be more than glad to cut prices down to a fraction of the drug's current level. And the chances that any of the drugs in Pfizer's development pipeline will come close to matching Lipitor's dizzyingly high sales are pretty slim. The most promising of Pfizer's candidates was torcetrapib, the first of a new class of heart drugs known as CEPT inhibitors. Torcetrapib showed promise in not only lowering "bad" cholesterol but increasing "good" cholesterol, which is widely viewed as the next step in the pharmaceutical treatment of cardiac disease. Pfizer sunk $800 million into developing torcetrapib and moving it to market as quickly as possible, aiming for a 2009 release. But the drug was scrapped in late 2006 when late-stage clinical trials showed substantially increased mortality rates among subjects who had taken it in combination with Lipitor. Now Pfizer's $800 million and one potential blockbuster down, and the clock is ticking until the Lipitor cash cow heads off to slaughter. Unless it can somehow discover, develop, test, and gain approval for a new wonder drug (a process that can easily take over a decade) in the next three years, Pfizer can expect both revenues and earnings to suffer.

Pfizer’s pipeline and current portfolio doesn’t seem to have any blockbusters that can make up the shortfall when Lipitor goes off patent protection. In other words, it doesn’t seem like Pfizer will be able to maintain current levels of revenues, earnings and cash flow once Lipitor goes off patent protection in 2 years.

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.